肝脏 ›› 2025, Vol. 30 ›› Issue (4): 490-494.

• 病毒性肝炎 • 上一篇    下一篇

血清干扰素-γ联合高迁移率族蛋白B1对巨细胞病毒性肝炎患儿预后的评估

占宏卓, 陈静佳   

  1. 435000 湖北 黄石市中心医院(湖北理工学院附属医院)儿科
  • 收稿日期:2024-07-03 出版日期:2025-04-30 发布日期:2025-06-17
  • 通讯作者: 陈静佳
  • 基金资助:
    湖北省自然科学基金项目(2020CFB410)

Assessment of the prognostic value of serum interferon-gamma combined with high mobility group box 1 in children with cytomegalovirus hepatitis

ZHAN Hong-zhuo, CHEN Jing-jia   

  1. Department of Pediatrics, Huangshi Central Hospital (Affiliated Hospital of Hubei University of Technology), Hubei 435000, China
  • Received:2024-07-03 Online:2025-04-30 Published:2025-06-17
  • Contact: CHEN Jing-jia

摘要: 目的 分析血清干扰素-γ(IFN-γ)联合高迁移率族蛋白B1(HMGB1)对巨细胞病毒(CMV)性肝炎患儿预后情况的评估。方法 回顾性收集2021年6月—2023年6月黄石市中心医院收治的126例CMV肝炎患儿的临床资料,将其设置为观察组,另外选取同期进行体检的73例健康儿童作为对照组。比较两组儿童的IFN-γ、HMGB、肝功能指标、免疫功能指标。观察组患儿均接受更昔洛韦治疗2周,根据患儿治疗后CMV DNA水平,将≤500 拷贝/mL设为预后良好组(n=91),其余为预后不良组(n=35),比较两组患儿治疗后的各项指标,通过logistic回归分析评估患儿预后情况的影响因素,并利用ROC曲线分析IFN-γ与HMGB评估患儿预后的诊断效能。结果 观察组患儿治疗前的IFN-γ、HMGB、AST、ALT、TBil水平分别为(14.3±2.7)mmol/L、(46.2±5.3)μg/L、(86.5±8.9)U/L、(82.1±8.3)U/L、(85.4±9.9)U/L,均高于对照组,且免疫指标更低;治疗后预后良好组患儿的IFN-γ、HMGB、AST、ALT、TBil水平分别为(5.3±1.7)mmol/L、(23.7±3.5)μg/L、(35.9±4.2)U/L、(36.4±4.3)U/L、(43.8±5.7)U/L,均低于预后不良组,且免疫指标更高(P<0.05);logistic分析显示,IFN-γ、HMGB、肝功能指标和免疫功能指标均是影响患儿预后的重要因素;ROC曲线显示,IFN-γ联合HMGB对预后情况评估的准确度为0.961(0.931, 0.991)。结论 血清IFN-γ联合HMGB1在CMV肝炎患儿预后的评估中具有较高的应用价值。

关键词: 干扰素-γ, 高迁移率族蛋白B1, 巨细胞病毒性肝炎, 诊断效能

Abstract: Objective To analyze the assessment of the prognostic situation of children with cytomegalovirus (CMV) hepatitis using serum interferon-gamma (IFN-γ) combined with high mobility group protein B1 (HMGB1). Methods Clinical data of 126 children with CMV hepatitis admitted to Huangshi Central Hospital from June 2021 to June 2023 were retrospectively collected and set as the observation group. Additionally, 73 healthy children undergoing routine physical examinations during the same period were selected as the control group. The two groups were compared for levels of IFN-γ, HMGB1, liver function and immune function. All children in the observation group received ganciclovir treatment for two weeks. Based on post-treatment CMV DNA levels, those with ≤ 500 copies/mL were categorized as the good prognosis group (n=91), while the rest were considered to as the poor prognosis group (n=35). The post-treatment indicators of both groups were compared. Logistic regression analysis was used to evaluate the factors influencing the prognosis of the children, and the diagnostic efficacy of IFN-γ and HMGB1 in assessing the prognostic situation was analyzed using ROC curves. Results Before treatment, the levels of IFN-γ, HMGB1, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBil) in the observation group were 14.3±2.7 mmol/L, 46.2±5.3 μg/L, 86.5±8.9 U/L, 82.1±8.3 U/L, and 85.4±9.9 U/L, respectively, all of which were higher than those in the control group, and their immune indicators were lower. After treatment, the levels of IFN-γ, HMGB1, AST, ALT, and TBil in the group with a good prognosis were 5.3±1.7 mmol/L, 23.7±3.5 μg/L, 35.9±4.2 U/L, 36.4±4.3 U/L, and 43.8±5.7 U/L, respectively, all lower than those in the group with a poor prognosis, and their immune indicators were higher, with statistical differences noted (P<0.05). Logistic analysis showed that IFN-γ, HMGB1, liver function indicators, and immune function indicators are all important factors affecting the prognosis of the children. The receiver operating characteristic (ROC) curve indicated that the combination of IFN-γ and HMGB1 had an accuracy of 0.961 (95% CI: 0.931, 0.991) in assessing the prognostic situation. Conclusion The combination of serum IFN-γ and HMGB1 have high application value in assessing the prognosis of children with cytomegalovirus hepatitis.

Key words: Interferon-gamma, High Mobility Group Box 1, Cytomegalovirus Hepatitis, Diagnostic Efficacy